These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3099095)

  • 1. Potentiation of hydroxyurea cytotoxicity in human chronic myeloid leukemia cells by iron-chelating agent.
    Satyamoorthy K; Chitnis MP; Basrur VS; Advani SH
    Leuk Res; 1986; 10(11):1327-30. PubMed ID: 3099095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro cytotoxicity of caracemide alone and in combination with hydroxyurea or iron-chelating agents in human chronic myeloid leukemia cells and murine tumors.
    Satyamoorthy K; Chitnis MP; Advani SH
    Neoplasma; 1988; 35(1):27-35. PubMed ID: 3162554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitization of P388 murine leukemia cells to hydroxyurea cytotoxicity by hydrophobic iron-chelating agents.
    Satyamoorthy K; Chitnis M; Basrur V
    Anticancer Res; 1986; 6(2):329-33. PubMed ID: 3518597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmentation of hydroxyurea cytotoxicity by sintamil in human chronic myeloid leukemia cells.
    Pradhan SG; Chitnis MP; Basrur VS; Satyamoorthy K; Advani SH
    Tumori; 1986 Oct; 72(5):507-10. PubMed ID: 3467512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperthermia blocks reversibility of hydroxyurea and bipyridine induced synergistic inhibition of DNA biosynthesis in P388 murine leukemia cells.
    Satyamoorthy K; Chitnis MP
    Neoplasma; 1988; 35(2):153-9. PubMed ID: 3374706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of hydroxyurea cytotoxicity by iron-chelating agent in murine tumor models in vitro.
    Satyamoorthy K; Chitnis MP; Pradhan SG
    Cancer Drug Deliv; 1986; 3(3):173-82. PubMed ID: 3779602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1,10-phenanthroline potentiates cytotoxicity of hydroxyurea in human chronic myeloid leukemia cells.
    Kamath NS; Satyamoorthy K; Chitnis MP; Advani SH
    Oncology; 1989; 46(3):193-7. PubMed ID: 2717131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea potentiation of the antineoplastic activity of cyclophosphamide and 4'-(9-acridinylamino)methanesulfon-M-anisidide (AMSA) in the brown Norway rat myelocytic leukemia model.
    Vaughan WP; Holm C; Cordel K
    Cancer Chemother Pharmacol; 1989; 23(1):26-30. PubMed ID: 2909287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
    Hehlmann R; Berger U; Pfirrmann M; Hochhaus A; Metzgeroth G; Maywald O; Hasford J; Reiter A; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Griesshammer M; Nerl C; Kuse R; Tobler A; Eimermacher H; Tichelli A; Aul C; Wilhelm M; Fischer JT; Perker M; Scheid C; Schenk M; Weiss J; Meier CR; Kremers S; Labedzki L; Schmeiser T; Lohrmann HP; Heimpel H;
    Leukemia; 2003 Aug; 17(8):1529-37. PubMed ID: 12886239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ferrous and ferric chelators on transferrin-iron-macrophage interactions.
    Baynes RD; Friedman BM; Bukofzer GT; Bothwell TH; Macfarlane BJ; Lamparelli RD
    Am J Hematol; 1988 Sep; 29(1):27-32. PubMed ID: 3177366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of human chronic myeloid leukemia cells to mitoxantrone cytotoxicity: potentiation by bepridil, a calcium channel antagonist.
    Parekh HK; Shallom JM; Advani SH; Chitnis MP
    Neoplasma; 1991; 38(6):575-81. PubMed ID: 1766484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea and 6-mercaptopurine in the treatment of chronic granulocytic leukemia.
    Lazzarino M; Morra E; Brusamolino E; Inverardi D; Castelli G; Merante S; Bernasconi C
    Am J Clin Oncol; 1986 Feb; 9(1):45-9. PubMed ID: 3513537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS; Liu DS; Dai CW; Li RJ
    Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ferrous iron chelator to treat subarachnoid haemorrhage.
    Fricker J
    Mol Med Today; 1997 Jun; 3(6):232. PubMed ID: 9211408
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of ferrous iron chelator 2,2'-dipyridyl in preventing delayed vasospasm in a primate model of subarachnoid hemorrhage.
    Horky LL; Pluta RM; Boock RJ; Oldfield EH
    J Neurosurg; 1998 Feb; 88(2):298-303. PubMed ID: 9452239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone & adriamycin cytotoxicity enhanced by reserpine in human chronic myeloid leukaemia cells.
    Chitnis MP; Kamath NS; Advani SH
    Indian J Med Res; 1989 Jun; 90():197-202. PubMed ID: 2767744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with interferon alfa-2b and hydroxyurea during the accelerated phase of chronic myelogenous leukemia.
    Bourantas KL; Syrou M; Tsiara S; Danella M; Konstantinides P
    Acta Haematol; 1996; 95(2):117-21. PubMed ID: 8638440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effect of dipyridyl, a liposoluble iron chelator against focal cerebral ischemia: in vivo and in vitro evidence of protection of cerebral endothelial cells.
    Méthy D; Bertrand N; Prigent-Tessier A; Mossiat C; Stanimirovic D; Beley A; Marie C
    Brain Res; 2008 Feb; 1193():136-42. PubMed ID: 18177633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; Kurzrock R; Keating MJ; McCredie KB; Gutterman J; Freireich EJ
    Acta Haematol; 1987; 78 Suppl 1():70-4. PubMed ID: 2449026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia.
    Gandhi V; Plunkett W; Kantarjian H; Talpaz M; Robertson LE; O'Brien S
    J Clin Oncol; 1998 Jul; 16(7):2321-31. PubMed ID: 9667246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.